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This paper contains additional data related to the research article
“Omega-3 fatty acids and mortality in patients referred for cor-
onary angiography – The Ludwigshafen Risk and Cardiovascular
Health Study” (Kleber et al., in press) [1]. The data shows char-
acteristics of the Ludwigshafen Risk and Cardiovascular Health
(LURIC) study according to tertiles of omega-3 fatty acids as well as
stratiﬁed by gender. The association of proportions of omega-3
fatty acids measured in erythrocyte membranes with different
causes of death is investigated with a special focus on modeling
the association of EPA with mortality in a nonlinear way. Further,
the association of omega-3 fatty acids with all-cause morta-vier Inc. This is an open access article under the CC BY license
/j.atherosclerosis.2016.06.049
edicine (Nephrology, Hypertensiology, Endocrinology, Diabetology,
lberg University, Mannheim, Germany.
delberg.de (M.E. Kleber).
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M.E. Kleber et al. / Data in Brief 8 (2016) 1311–13211312lity adjusted for high-sensitive C-reactive protein as a marker of
systemic inﬂammation is examined as well as the association of
EPA with cause-speciﬁc death.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Medicine
ore speciﬁc sub-
ject areaCardiovascular diseasesype of data Table, graph, ﬁgures
ow data was
acquiredErythrocyte omega-3 fatty acid proportions were measured at baseline in
3259 participants of the Ludwigshafen Risk and Cardiovascular Health Study
(LURIC) using the HS-Omega-3 Index method. Associations of omega-3 fatty
acid proportions with mortality were investigated using Cox proportional
hazards regression.ata format Analyzed
xperimental
factorsFasting blood samples were obtained by venipuncture at study entry. Fatty
acid methyl esters were generated from erythrocytes that had been stored at
80 °C by acid transesteriﬁcation.xperimental
featuresErythrocyte fatty acid composition was analyzed according to the HS-
Omega-3 Index technology [2]. Fatty acid methyl esters were analyzed by gas
chromatography using a GC2010 gas chromatograph (Shimadzu, Duisburg,
Germany) equipped with a 100-m SP2560 column (Supelco, Bellefonte, PA)
and using hydrogen as carrier gas. Fatty acids were identiﬁed by comparison
with a standard mixture of fatty acids characteristic of erythrocytes. Results
are presented as a percentage of total identiﬁed fatty acids after response
factor correction.ata source
locationLudwigshafen Heart Center in South-West Germanyata accessibility Data is within this article.Value of the data
 Gender-stratiﬁed analysis allows the identiﬁcation of gender-speciﬁc effects of omega-3 fatty acids.
 Examination of nonlinear effects on mortality risk is important to deﬁne safe reference values.
 Investigation of cause-speciﬁc mortality might provide hints to possible pathways affected by
omega-3 fatty acids.1. Data
The data presented in this paper includes Figures and Tables that show the results of gender and
subgroup stratiﬁed distribution of omega-3 fatty acids proportions in the LURIC study as well as
multivariate adjusted analyses of their association with all-cause and cause-speciﬁc mortality that
extend the results reported in [1] (Figs. 1–7 and Tables 1–6).
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2.1. Subjects
The LURIC study consists of 3316 Caucasians with an indication for coronary angiography that
were between 1997 and 2000 at the Ludwigshafen Heart Center in South-West Germany. A detailed
description of the study can be found in Winkelmann et al. [3]. The study was approved by the
'Landesärztekammer' Ethics Committee of the Rheinland-Pfalz state in Germany. Informed written
consent was obtained from all participants.2.2. Laboratory procedures
The fatty acid composition of erythrocyte membranes was analyzed using the HS-Omega-3 Indexs
methodology as described in [1,2]. Results are given as a percentage of total identiﬁed fatty acids after
response factor correction.Fig. 1. Proportions of omega-3 fatty acids in men and women. Box plots showing the distribution of ALA (A), EPA (B), DHA
(C) and DPA (D) in LURIC stratiﬁed by gender. Boxes represent the interquartile ranges (IQR), median values are shown as black
lines. Whiskers extend to the data point closest to a distance 1.5 times the IQR away from the median. ALA: α-linolenic acid;
EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; DPA: docosapentaenoic acid.
Fig. 2. Density distribution of omega-3 fatty acid levels in men and women. Density plots showing the density distributions of
ALA (A), EPA (B), DHA (C) and DPA (D) stratiﬁed by gender. ALA: α-linolenic acid; EPA: eicosapentaenoic acid; DHA: doc-
osahexaenoic acid; DPA: docosapentaenoic acid.
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The deﬁnition of clinical endpoints is detailed in [1,3]. The 2012 CKD-EPI eGFRcreat-cys equation
was used to estimate the glomerular ﬁltration rate [4]. Information on vital status of study partici-
pants was requested from local registries. Cardiovascular mortality included sudden cardiac death
(n¼254, 7.8%), fatal myocardial infarction (n¼104, 3.2%), death due to congestive heart failure
(n¼148, 4.5%), death after intervention to treat CAD (n¼26, 0.8%), fatal stroke (n¼60, 1.8%), and other
causes of death due to CAD (n¼19, 0.6%).
2.4. Statistical analyses
We present the mean and the standard deviation of continuous data when normally distributed
and the median and 25th and 75th percentile for variables with a skewed distribution. Categorical
data are presented as percentages. ANOVAwas used to compare continuous variables between groups
(variables with a skewed distribution were log-transformed before entering analysis) and the chi-
square test was used for categorical variables. The association of omega-3 fatty acid levels in tertiles
Fig. 4. Association of omega-3 fatty acids with mortality additionally adjusted for hsCRP. Forest plot showing the risk of mortality per
1-SD increase in omega-3 fatty acids. Hazard ratios with 95% conﬁdence intervals were calculated by Cox regression adjusted for age
and gender, BMI, LDL-C, HDL-C, logTG, hypertension, diabetes, smoking, alcohol consumption, physical exercise, lipid lowering therapy
and log hsCRP.
Fig. 5. Association of DPAwith mortality. Forest plot showing the risk of all-cause mortality and CVM per 1-SD increase in DPA.
Model 1: adjusted for age and gender; model 2: additionally adjusted for BMI, LDL-C, HDL-C, logTG, hypertension, diabetes,
smoking, alcohol consumption, physical exercise and lipid lowering therapy. DPA: docosapentaenoic acid.
Fig. 3. Association of omega-3 fatty acids with cardiovascular mortality. Forest plot showing the risk of CVM per 1-SD increase in
omega-3 fatty acids. Hazard ratios and 95% CI were calculated for ALA, EPA, DHA and the HS-Omega-3 Index by Cox regression.
Model 1: adjusted for age and gender; model 2: additionally adjusted for BMI, LDL-C, HDL-C, logTG, hypertension, diabetes,
smoking, alcohol consumption, physical exercise and lipid lowering therapy. ALA: α-linolenic acid; EPA: eicosapentaenoic acid; DHA:
docosahexaenoic acid; DPA: docosapentaenoic acid; TG: triglycerides.
Fig. 6. Association of omega-3 fatty acids with all-cause mortality stratiﬁed by CAD status. Hazard ratios and 95% CI were
calculated for ALA, EPA, DHA and the HS-Omega-3 Index using Cox regression in patients with (A) and without (B) CAD at
baseline. Model 1: adjusted for age and gender; model 2: additionally adjusted for BMI, LDL-C, HDL-C, logTG, hypertension,
diabetes, smoking, alcohol intake, physical exercise and lipid lowering therapy. ALA: α-linolenic acid; EPA: eicosapentaenoic
acid; DHA: docosahexaenoic acid; TG: triglycerides.
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Fig. 7. Hazard ratio plots showing the relationship between EPA proportion and all-cause mortality. Results are shown for men
(A) and women (B). In a Cox regression model including age, sex, BMI, LDL-C, HDL-C, TG, smoking, alcohol intake, diabetes
mellitus, hypertension, physical exercise, lipid lowering therapy and EPA, the EPA proportion was modeled as restricted cubic
spline with three knots and plotted against the log hazard. EPA: eicosapentaenoic acid.
M.E. Kleber et al. / Data in Brief 8 (2016) 1311–1321 1317or as Z-transformed values with mortality was assessed by Cox proportional hazard regression with
the same adjustments as in [1]. Examination of scaled Schoenfeld residuals provided no evidence for a
violation of the proportional hazard assumption. All tests were two-sided and a p value o0.05 was
considered statistically signiﬁcant. SPSS v22.0 (IBM, Ehningen, Germany) and R v3.2.3 (http://www.r-
project.org) were used for all analyses. The R-package 'rms' was used for the generation of hazard
ratio plots.Grant support
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Table 1
Study characteristics stratiﬁed by gender (mean7SD or median and 25th–75th percentile).
Male Female pa
N¼2270 N¼989
Age (years) 61.8 (64.7) 64.7 (10.2) o0.001
BMI (kg/m2) 27.6 (3.78) 27.3 (4.66) 0.103
LDL-C (mmol/L) 2.95 (0.84) 3.16 (0.98) o0.001
HDL-C (mmol/L) 0.97 (0.26) 1.08 (0.31) o0.001
TG (mmol/L) 1.67 (1.24–2.28) 1.63 (1.20–2.26) 0.016
Systolic blood pressure (mmHg) 141 (23.2) 141 (24.6) 0.870
Diastolic blood pressure (mmHg) 81.7 (11.5) 79.5 (11.4) o0.001
Fasting glucose (mmol/L) 5.70 (5.23–6.59) 5.64 (5.14–6.56) 0.004
hsCRP (mg/L) 3.28 (1.24–8.63) 3.58 (1.45–8.63) 0.107
NT-proBNP (ng/ml) 286 (98.0–858) 313 (132–878) 0.002
RBC ALA (%) 0.118 (0.046) 0.123 (0.045) 0.001
RBC EPA (%) 0.77 (0.32) 0.75 (0.28) 0.053
RBC DPA (%) 2.47 (0.36) 2.36 (0.336) o0.001
RBC DHA (%) 5.05 (1.12) 5.12 (1.02) 0.102
RBC HS-Omega-3 Index (%) 5.82 (1.33) 5.86 (1.19) 0.365
CAD (%) 83.6 64.7 o0.001
Diabetes mellitus (%) 40.1 39.0 0.586
Hypertension (%) 71.4 76.2 0.005
Arrhythmia (%) 15.4 13.1 0.930
Smoking (active/ex/never) (%) 26.2/50.7/23.0 17.2/19.0/63.8 o0.001
Lipid lowering therapy (%) 50.6 43.9 o0.001
a t-test for continuous variables (non-normally distributed variables were log transformed before entering analysis), χ2 test
for categorical variables.
Table 2
Study characteristics according to tertiles of α-linoleic acid (mean7SD or median and 25th–75th percentile).
ALA (% of total fatty acids)
r0.10 0.11–0.13 Z0.14 pa
N¼1384 N¼952 N¼923
Age (years) 63.5710.6 62.8710.8 61.5710.4 o0.001
Sex (% male) 72.7 69.3 65.4 0.001
BMI (kg/m2) 27.673.99 27.474.07 27.574.18 0.455
LDL-C (mg/dl) 114732.1 117735.1 120736.4 o0.001
HDL-C (mg/dl) 37.4710.1 39.3711.2 40.5711.4 o0.001
TG (mg/dl) 136 (103–185) 144 (107–197) 166 (120–236) o0.001
LDL radius (nm) 8.2870.20 8.2870.23 8.2870.24 0.815
Systolic blood pressure (mmHg) 141723.8 141723.4 141723.6 0.967
Diastolic blood pressure (mmHg) 80.1711.6 81.2711.6 82.1711.1 o0.001
Fasting glucose (mg/dl) 102 (92.7–118) 103 (94.0–118) 103 (95.0–119) 0.104
hsCRP (mg/L) 4.28 (1.50–10.1) 3.28 (1.33–8.35) 2.60 (1.12–6.18) o0.001
NT-proBNP (ng/ml) 367 (139–1029) 278 (100–848) 214 (86.0–604) o0.001
CAD (%) 82.5 75.4 73.5 o0.001
Diabetes (%) 40.9 39.9 37.9 0.357
Hypertension (%) 73.3 72.2 72.9 0.821
Arrhythmia (%) 15.0 16.0 12.9 0.147
Smoking (active/ex/never) (%) 22.9/44.6/32.5 23.0/36.9/40.1 24.8/40.1/35.1 0.001
Lipid lowering therapy (%) 53.8 47.4 42.0 o0.001
a ANOVA for continuous variables (non-normally distributed variables were log transformed before entering analysis),
χ2 test for categorical variables.
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Table 3
Study characteristics according to tertiles of eicosapentaenoic acid (mean7SD or median and 25th–75th percentile).
EPA (% of total fatty acids)
r0.60 0.61–0.62 Z0.83 pa
n¼1096 n¼1115 n¼1048
Age (years) 63.0710.9 62.3711.0 62.879.9 0.261
Sex (% male) 68.8 69.6 70.6 0.658
BMI (kg/m2) 27.474.0 27.574.2 27.574.0 0.830
LDL-C (mg/dl) 112.1732.4 116.8735.1 120.8734.8 o0.001
HDL-C (mg/dl) 37.0710.1 38.4710.2 41.1711.8 o0.001
TG (mg/dl) 153(113–210) 150(112–206) 136(102–187) o0.001
LDL radius (nm) 8.2770.21 8.2870.23 8.3070.22 0.015
Systolic blood pressure (mmHg) 141723.6 140723.9 142723.4 0.295
Diastolic blood pressure (mmHg) 80.7711.5 80.7711.6 81.7711.3 0.076
Fasting glucose (mg/dl) 102(93.7–120) 102(93.6–119) 102(93.6–116) 0.279
hsCRP (mg/L) 3.74(1.38–9.30) 3.35(1.35–8.56) 3.02(1.18–7.99) 0.005
NT-proBNP (ng/ml) 352(136–1118) 274(97.0–773) 248(98.0–756) o0.001
CAD (%) 78.7 78.5 76.3 0.341
Diabetes (%) 43.2 39.1 36.8 0.009
Hypertension (%) 73.9 72.4 72.3 0.642
Arrhythmia (%) 15.5 15 13.6 0.446
Smoking (active/ex/never) (%) 24.4/41.8/33.9 24.2/38.7/37.0 21.8/42.7/35.5 0.210
Lipid lowering therapy (%) 49.5 49.7 46.4 0.224
a ANOVA for continuous variables (non-normally distributed variables were log transformed before entering analysis),
χ2 test for categorical variables.
Table 4
Study characteristics according to tertiles of docosahexaenoic acid (mean7SD or median and 25th–75th percentile).
DHA(% of total fatty acids)
r4.53 4.54–5.47 Z5.48 pa
n¼1090 n¼1084 n¼1085
Age (years) 60.1711.2 62.6710.5 65.379.46 o0.001
Sex (% male) 72.4 69.3 67.3 0.033
BMI (kg/m2) 27.274.1 27.774.0 27.474.1 0.017
LDL-C (mg/dl) 117.4733.2 117.2734.6 114.8735.0 0.145
HDL-C (mg/dl) 38.9710.8 38.4710.4 39.1711.4 0.318
TG (mg/dl) 156(112–216) 149(113–203) 135(102–187) o0.001
LDL radius (nm) 8.2770.21 8.2870.23 8.2970.22 0.114
Systolic blood pressure (mmHg) 140723.6 141723.8 142723.4 0.237
Diastolic blood pressure (mmHg) 81.3711.7 81.0711.5 80.7711.2 0.391
Fasting glucose (mg/dl) 101(93.2–115) 104(94.4–120.9) 102(93.4–119) 0.122
hsCRP (mg/L) 3.32(1.24–7.91) 3.57(1.38–9.24) 3.34(1.23–8.54) 0.107
NT-proBNP (ng/ml) 276(95.8–757) 292(105–934) 311(116–921) 0.013
CAD (%) 75.2 78.5 79.9 0.026
Diabetes (%) 35.2 42.3 41.8 0.001
Hypertension (%) 70.9 74.3 73.5 0.187
Arrhythmia (%) 13.5 13.8 16.9 0.051
Smoking (active/ex/never) (%) 33.0/36.2/30.7 23.5/42.4/34.0 13.8/44.5/41.7 o0.001
Lipid lowering therapy (%) 47.0 48.5 50.2 0.315
a ANOVA for continuous variables (non-normally distributed variables were log transformed before entering analysis),
χ2 test for categorical variables.
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Table 5
Comparison of Cox regression analyses modeling EPA proportion as linear term or as restricted cubic spline adjusted for risk
factors (model 2).
loglik Chisq Df p
Combined
Spline model 7151.0
Linear model 7153.5 4.9778 1 0.02567
Men
Spline model 5072.7
Linear model 5076.3 7.1767 1 0.007386
Women
Spline model 1519.7
Linear model 1519.9 0.3817 1 0.5367
Table 6
Association between omega-3 fatty acids and cause-speciﬁc death.
Death due to heart failure Sudden cardiac death
HR (95% CI) p HR (95% CI) p
a-Linolenic acid
Model 1 1st (r0.10%) 1reference 1reference
2nd (0.11–0.13%) 0.75 (0.50–1.12) 0.154 0.77 (0.57–1.04) 0.088
3rd (Z0.14%) 0.96 (0.65–1.42) 0.838 0.96 (0.71–1.29) 0.761
pTrend 0.346 0.222
Model 2 1st (r0.10%) 1reference 1reference
2nd (0.11–0.13%) 0.79 (0.53–1.19) 0.258 0.80 (0.59–1.09) 0.159
3rd (Z0.14%) 1.05 (0.69–1.58) 0.831 1.05 (0.77–1.44) 0.764
pTrend 0.422 0.252
Eicosapentaenoic acid
Model 1 1st (r0.60%) 1reference 1reference
2nd (0.61–0.82%) 0.71 (0.49–1.04) 0.077 0.93 (0.69–1.24) 0.600
3rd (Z0.83%) 0.62 (0.42–0.93) 0.020 0.71 (0.52–0.98) 0.034
pTrend 0.044 0.094
Model 2 1st (r0.60%) 1reference 1reference
2nd (0.61–0.82%) 0.77 (0.52–1.13) 0.184 0.98 (0.73–1.31) 0.886
3rd (Z0.83%) 0.69 (0.46–1.04) 0.076 0.75 (0.54–1.04) 0.081
pTrend 0.167 0.165
Docosahexaenoic acid
Model 1 1st (r4.53%) 1reference 1reference
2nd (4.54–5.47%) 0.80 (0.53–1.20) 0.273 1.03 (0.76–1.41) 0.833
3rd (Z5.48%) 0.85 (0.57–1.26) 0.411 0.94 (0.69–1.28) 0.700
pTrend 0.525 0.815
Model 2 1st (r4.53%) 1reference 1reference
2nd (4.54–5.47%) 0.76 (0.50–1.15) 0.197 0.95 (0.69–1.30) 0.741
3rd (Z5.48%) 0.84 (0.56–1.26) 0.388 0.91 (0.66–1.26) 0.574
pTrend 0.425 0.853
HS-Omega-3 Index
Model 1 1st (r5.19%) 1reference 1reference
2nd (5.20–6.24%) 0.74 (0.49–1.10) 0.137 1.11 (0.82–1.50) 0.517
3rd (Z6.25%) 0.77 (0.52–1.13) 0.182 0.85 (0.62–1.16) 0.305
pTrend 0.260 0.212
Model 2 1st (r5.19%) 1reference 1reference
2nd (5.20–6.24%) 0.73 (0.49–1.10) 0.133 1.04 (0.76–1.41) 0.822
3rd (Z6.25%) 0.78 (0.52–1.16) 0.221 0.82 (0.60–1.14) 0.242
pTrend 0.278 0.303
Model 1: adjusted for age and gender.
Model 2: additionally adjusted for LDL-C, HDL-C, logTG, BMI, hypertension, diabetes mellitus, smoking, alcohol intake, physical
exercise and lipid lowering therapy.
M.E. Kleber et al. / Data in Brief 8 (2016) 1311–13211320
M.E. Kleber et al. / Data in Brief 8 (2016) 1311–1321 1321Acknowledgments
We thank the LURIC study team which was either temporarily or permanently involved in patient
recruitment as well as sample and data handling, in addition to the laboratory staff at the Ludwig-
shafen General Hospital and the Universities of Freiburg and Ulm, Germany.Transparency document. Supplementary material
Transparency data associated with this article can be found in the online version at http://dx.doi.
org/10.1016/j.dib.2016.07.051.References
[1] M.E. Kleber, G.E. Delgado, S. Lorkowski, et al., Omega-3 fatty acids and mortality in patients referred for coronary angio-
graphy. The Ludwigshafen Risk and Cardiovascular Health Study, Atherosclerosis (2016), pii: S0021-9150(16)30294-5.
http://dx.doi.org/10.1016/j.atherosclerosis.2016.06.049. [Epub ahead of print].
[2] A. Kohler, D. Bittner, A. Low, et al., Effects of a convenience drink fortiﬁed with n-3 fatty acids on the n-3 index, Br. J. Nutr.
104 (2010) 729–736.
[3] B.R. Winkelmann, W. Marz, B.O. Boehm, et al., Rationale and design of the LURIC study–a resource for functional genomics,
pharmacogenomics and long-term prognosis of cardiovascular disease, Pharmacogenomics 2 (2001) S1–73.
[4] L.A. Inker, C.H. Schmid, H. Tighiouart, et al., Estimating glomerular ﬁltration rate from serum creatinine and cystatin C, N.
Engl. J. Med. 367 (2012) 20–29.
